Aptinyx Inc. (APTX)
(Delayed Data from NSDQ)
$3.78 USD
+0.03 (0.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.79 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.78 USD
+0.03 (0.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.79 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Aptinyx Inc. (APTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 6.90% and -41.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Aptinyx (APTX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (APTX) Outperforming Other Medical Stocks This Year?
Aptinyx Inc. (APTX) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aptinyx's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aptinyx.
Aptinyx Inc. (APTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of -3.03% and -9.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Aptinyx Inc (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aptinyx Inc (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for May 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 6th
The Zacks Analyst Blog Highlights: Airgain, Trilogy Metals, Aptinyx, Veritone and Tufin Software Technologies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Airgain, Trilogy Metals, Aptinyx, Veritone and Tufin Software Technologies
Small Caps Bounce Back: Buy 5 Stocks With Strong Balance Sheet
by Sanghamitra Saha
Relative underperformance compared to the large caps, a super-dovish Fed and the U.S. government's gigantic aid toward small-and-mid-cap stocks have boosted pint-sized stocks lately.
Will Aptinyx Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Aptinyx
Aptinyx Inc. (APTX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.51% and -2.96%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aptinyx Inc. (APTX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Aptinyx Inc. (APTX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aptinyx Inc. (APTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 4.35% and 2.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aptinyx Inc. (APTX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aptinyx's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aptinyx.
Will Aptinyx Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Aptinyx.
Zacks Market Edge Highlights: Google, Cisco, Aptinyx, Uber and Lyft
by Zacks Equity Research
Zacks Market Edge Highlights: Google, Cisco, Aptinyx, Uber and Lyft
How Young Investors Find the Next Google
by Tracey Ryniec
Sometimes stock ideas and trends can present themselves in unlikely places. If you're paying attention.
Aptinyx Inc. (APTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.77% and -2.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Aptinyx's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aptinyx.
All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy
by Zacks Equity Research
Aptinyx Inc. (APTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allergan's Depression Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants fast track designation to Allergan's (AGN) AGN-241751, developed for the treatment of patients with major depressive disorder.